Breaks Categories: News

WednesdayFeb 28, 2024 2:48 pm

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Strategic Appointment of Garrett Gardi

HealthLynked (OTCQB: HLYK), a leader in health care technology solutions for patients and providers, has announced the addition of Garrett Gardi to its advisory board. Gardi has more than two decades of experience in employee benefit plans, specializing in predictive cost analytics, consumer-driven platforms, and self-funded/alternative funding methodologies, and brings a wealth of knowledge and expertise to the HealthLynked team. “Garrett’s addition to our advisory board marks a significant milestone for HealthLynked as we continue to expand our reach and impact in the health care sector,” said Dr. Michael Dent, CEO of HealthLynked. “His extensive experience and innovative approach to…

Continue Reading

WednesdayFeb 28, 2024 1:22 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board of Directors Approves Debt Settlement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has announced a debt settlement. According to the announcement, the company’s board of directors approved the settlement of $637,650 owed to arm's length creditors through issuing 545,000 Class B subordinate voting shares in the capital of the corporation; the shares were issued at $1.17 per share. The board also approved the granting of 55,000 restricted share units (“RSUs”) to consultants of the company according to FSD Pharma’s equity incentive plan, with each RSU good for the acquisition of…

Continue Reading

WednesdayFeb 28, 2024 12:01 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports on Year-End 2023 Financial Results, Corporate Update

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report also included a corporate update. The report noted that revenues for 2023 totaled $0.7 million with grant revenue for 2023 being less than $0.1 million; related cost of revenues was $0.5 million for 2023; and gross profit for the year came in at approximately $0.2 million. In addition, general and administrative expenses totaled $11.4 million for 2023; research and development expenses decreased to approximately $9.1 million with selling and marketing expenses for…

Continue Reading

MondayFeb 26, 2024 1:50 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Subsidiary Enter Agreement for Clinical Trial of Proprietary Blend Beverage

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, and its subsidiary, HUGE Biopharma Australia Pty Ltd., have entered into an agreement with Ingenu CRO Pty Ltd. The agreement outlines a study to assess the safety and efficacy of unbuzzd(TM), a fortified oral liquid formula, being used as a treatment with healthy volunteers who are in an induced state of alcohol intoxication. According to the announcement, the trial is a key step in verifying that unbuzzd helps a person sober up faster from the effects of alcohol.…

Continue Reading

ThursdayFeb 22, 2024 1:19 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today reported new, significant survival results in amyotrophic lateral sclerosis (“ALS”) patients. According to the announcement, the results are from two independent analyses of pooled data from two intermediate-size “Companionate Use” Expanded Access Programs (“EAPs”) supported by the company. The EAPs provided access to treatment with CNM-Au8(R) to 256 participants, all people living with ALS who were generally too advanced in their disease to qualify for clinical…

Continue Reading

ThursdayFeb 22, 2024 11:37 am

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Plans to Release Year-End 2023 Financial Results, Corporate Update

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has scheduled a conference call to discuss its financial results for 2023. The company announced that it will release its 2023 financial results after market close on Feb. 27, 2024, and will host a conference call at 5 p.m. ET that same day. During the call, company officials will provide an overview of the financial report as well as a corporate update. Those interested in participating on the call can dial 1-877-407-0789, then use conference ID 13744350. To view the webcast, visit https://ibn.fm/stZJx To view the…

Continue Reading

WednesdayFeb 21, 2024 1:51 pm

BioMedNewsBreaks – Modular Medical Inc. (NASDAQ: MODD) Announces Pricing of $10M Public Offering

Modular Medical (NASDAQ: MODD), a development-stage insulin delivery technology company seeking to launch the next generation of easy-to-use and affordable insulin pump technology, previously announced the pricing of its underwritten public offering of 9,090,910 shares of its common stock. The offering is led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical’s chief executive officer, Morgan Frank, a member of the company’s board of directors, as well as other existing institutional investors. The shares of common stock are each being sold at a price to the public of $1.10. In addition, Modular Medical granted the underwriter a…

Continue Reading

TuesdayFeb 20, 2024 1:36 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Market Offering Agreement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an agreement. The market offering agreement is with H.C. Wainwright & Co. LLC. According to the agreement, FSD Pharma may offer and sell Class B subordinate voting shares in the capital of the company at its discretion. The offering may total up to $11,154,232. The announcement also noted that Wainwright will receive a 3% cash commission on the gross proceeds of the offering. The sales of the Class B shares can be made whenever FSD…

Continue Reading

TuesdayFeb 20, 2024 12:13 pm

BioMedNewsBreaks — Astiva Health Opens Doors to New LA-Koreatown Activity Center, Marks ‘Testament’ to Empowering Seniors

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, has opened a new facility in Los Angeles. The company is celebrating the Dec. 16, 2023, opening of its Los Angeles-Koreatown Activity Center. The grand-opening ceremony, which marked a milestone for Astiva in its efforts to serve the senior community of Koreatown, included a ribbon cutting by Congresswoman Michelle Steel. According to the announcement, the new activity center will offer health education and wellness activities for seniors in Koreatown and is designed to be a center for senior care. The new center,…

Continue Reading

ThursdayFeb 15, 2024 2:49 pm

BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes on $10M Public Offering

Sunshine Biopharma (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, has closed on a firm commitment underwritten public offering. The offering is comprised of 71,428,571 units, including 26,428,571 common units and 45,000,000 prefunded units. According to the announcement, the offering is projected to result in approximately $10 million gross proceeds, before the deduction of underwriting discounts and other estimated expenses. Sunshine Biopharma also granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock, prefunded warrants and Series A warrants or Series B warrants sold…

Continue Reading